; (5) each State agency that administers the PDMP to— (A) proactively analyze data available through the PDMP; and (B) provide reports to law enforcement agencies and prescriber licensing boards describing any prescribing practitioner that repeatedly fall outside of expected norms or standard practices for the prescribing practitioner’s field; and (6) that the data contained in the PDMP of the covered State be made available to other States. (c) Noncompliance If a covered State fails to comply with subsection (a), the Attorney General or the Secretary of Health and Human Services may withhold grant funds from being awarded to the covered State under the Harold Rogers Prescription Drug Monitoring Program established under the Departments of Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations Act, 2002 ( Public Law 107–77 ; 115 Stat. 748), under this Act (or an amendment made by this Act), or under the controlled substance monitoring program under section 399O of the Public Health Service Act ( 42 U.S.C. 280g–3 ). 14. Increasing civil and criminal penalties for opioid manufacturers Section 402(c) of the Controlled Substances Act ( 21 U.S.C. 842(c) ) is amended— (1) in paragraph (1)(B), by striking shall not exceed $10,000. and inserting the following: “shall not exceed— (i) except as provided in clause (ii), $10,000; and (ii) if the violation is committed by a manufacturer of opioids and relates to the reporting of suspicious orders for opioids or failing to maintain effective controls against diversion of opioids, $100,000. ; and (2) in paragraph (2)— (A) in subparagraph (A), by inserting or (D) after subparagraph (B)